Gergely Toth, PhD, MBA
University of Cambridge
Dr. Toth is affiliated with the University of Cambridge, as an investigator in the NIHR Biomedical Research Unit on Dementia and of the Neurodegenerative Disease Initiative on AD by the WT and MRC (see his profile here)
His research interests are the biophysical/structural biology aspects and therapeutic targeting of proteins that misfold and lose their native functions and/or gain toxic functions. Dr. Toth is also the founder and CEO of Gardedam Therapeutics. He received a MS in Chemistry from the University of Szeged (Hungary), a PhD in Biomedical Sciences from Creighton University (USA), and an Executive MBA from the University of Cambridge (UK).